Cantex Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Development for CX-02 in Recurrent Glioblastoma

WESTON, Fla., May 1, 2017 /PRNewswire/ -- Cantex Pharmaceuticals Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals that improve the treatment of cancers and other life-threatening disorders, today announced that dosing has been initiated in its Phase 2 clinical trial for CX-02, Cantex's proprietary combination of disulfiram + copper (DSF-Cu), in recurrent glioblastoma. The trial's principal investigator is Jiayi Huang, M.D., at Washington University School of Medicine in St. Louis.

"Evidence found in pre-clinical studies has strongly indicated that DSF-Cu has cancer cell-killing effects against glioblastoma, breast cancer, prostate cancer, and other forms of cancer," said Stephen Marcus, M.D., Chief Executive Officer of Cantex Pharmaceuticals, Inc. "Among the encouraging pre-clinical data is evidence that DSF-Cu can re-sensitize glioblastoma stem cells to the beneficial effects of temozolomide, the most effective existing pharmaceutical treatment of glioblastoma. With the initiation of human dosing in our Phase 2 trial in recurrent glioblastoma, we look forward to exploring CX-02's potential efficacy and tolerability in this challenging illness. Glioblastoma multiforme is an aggressive malignant brain tumor in great need of new and more effective treatments."

The Phase 2 multicenter, open-label, single-arm study will evaluate the efficacy, safety, and tolerability of CX-02 in approximately 20 patients with recurrent glioblastoma. The endpoints of the study will include response rate per RANO criteria, progression-free survival at six months, and overall survival. Top-line results of the endpoints evaluated in this trial are expected in late 2017 and during the first half of 2018.

About Cantex Pharmaceuticals, Inc.

Cantex Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing proprietary pharmaceuticals that improve the treatment of cancers and other life-threatening disorders. Cantex's CX-02 is a proprietary combination of disulfiram + copper.  CX-02 is currently in a Phase II clinical trial for recurrent glioblastoma, with plans to initiate additional Phase II trials in metastatic prostate cancer and metastatic breast cancer in the second half of 2017 and in 2018. Cantex's second clinical stage product, CX-01, is being developed for the treatment of acute myeloid leukemia (AML) and other blood disorders. A randomized Phase IIB trial of CX-01 in newly diagnosed AML and a Phase II trial of CX-01 in patients with myelodysplastic syndrome are currently enrolling patients. For more information, please visit www.cantex.com.

SOURCE Cantex Pharmaceuticals, Inc.

Related Links

http://www.cantex.com